UMBS-seq (ultra-mild bisulfite sequencing) is a bisulfite conversion method developed by researchers at the University of Chicago that achieves highly efficient cytosine-to-uracil conversion — >99.8% in its downstream commercial kit form — while dramatically reducing DNA degradation compared with conventional bisulfite sequencing (CBS-seq) and enzymatic methyl-sequencing (EM-seq). By pairing a low reaction temperature (55 °C) with an optimized high-concentration ammonium bisulfite recipe and a DNA-protective buffer, UMBS-seq produces higher library yield, greater library complexity, longer DNA insert sizes, and more accurate methylation calls from cell-free DNA (cfDNA) inputs as low as 10 pg.
What Problem Does UMBS-seq Solve?
DNA methylation — especially 5-methylcytosine (5mC) — is one of the most clinically important epigenetic marks. Aberrant 5mC patterns are strongly linked to cancer and other diseases, and cell-free DNA methylation is an increasingly important biomarker for early disease detection and minimal residual disease (MRD). But mapping 5mC at base resolution has always meant choosing between tradeoffs in the two dominant approaches:
- Conventional bisulfite sequencing (CBS-seq). Many suppliers offer conventional bisulfite conversion kits; the University of Chicago team benchmarked against a common one, EZ DNA Methylation-Gold (Zymo Research). Depending on the supplier, the CBS-seq conversion step can be relatively fast (Zymo Gold uses a conversion step of over 2.5 hours), robust, and automation-compatible — but the harsh chemistry causes severe DNA damage, incomplete conversion in GC-rich regions, and systematic overestimation of methylation levels. All three are especially damaging for low-input or fragmented samples like cfDNA and FFPE-derived DNA.
- Enzymatic methyl-sequencing (EM-seq). Methods such as the NEBNext® Enzymatic Methyl-seq Kit, also tested in the study, avoid bisulfite-induced DNA damage by using enzymatic TET2 oxidation and APOBEC deamination in place of chemical conversion. But they carry their own drawbacks: incomplete cytosine conversion at low inputs, enzyme instability, a long and complex full-workday workflow, and high reagent costs.
The University of Chicago team behind this work, led by Professor Chuan He, had previously developed ultrafast bisulfite sequencing (UBS-seq), which shortened bisulfite reaction times to minutes and reduced background noise. But DNA degradation remained a critical bottleneck, particularly for precious low-input samples. The expanded team — senior author Chuan He with Qing Dai, Tanner Baldwin, Ruitu Lyu, Bryan Daniels, Chang Ye, Chen Cao, Chenyou Zhu, Diwen Fan, Liane Lin, Yushuai Liu, and Yiding Wang — tackled that remaining degradation problem directly, publishing their findings in Nature Communications in 2025 as “Ultra-mild bisulfite outperforms existing methods for 5-methylcytosine detection with low input DNA.”
How Does UMBS-seq Work?
Bisulfite-mediated cytosine deamination depends heavily on two factors: bisulfite concentration and reaction pH. Higher bisulfite concentration drives more efficient conversion, while pH controls both the protonation step the reaction requires and the balance between active bisulfite and inactive sulfite species in solution.
Rather than pushing the reaction harder and faster, as UBS-seq did at 98 °C for around 10 minutes, UMBS-seq takes the opposite approach. The team optimized bisulfite concentration and pH to enable efficient conversion at a much lower temperature — 55 °C for 90 minutes — minimizing the thermal DNA damage that drives conventional bisulfite fragmentation. Four innovations distinguish UMBS-seq from the earlier UBS-seq protocol:
- A new bisulfite recipe. UMBS-seq uses a high ammonium bisulfite solution and pH, giving finer control over both pH and bisulfite concentration.
- A DNA protection buffer. An added organic solvent and antioxidant buffer helps prevent DNA renaturation and further reduces damage during the reaction.
- Gentler denaturation. DNA is pre-denatured with a 20-minute incubation rather than relying on high reaction temperature to melt the double helix.
- A lower-temperature conversion reaction. The 55 °C / 90-minute protocol allows a substantial reduction in DNA degradation.
Key Findings from the Paper
Substantially less DNA damage than conventional bisulfite sequencing
Bioanalyzer-based fragment analysis showed that UMBS-seq caused significantly less DNA fragmentation on intact lambda (λ) DNA than the earlier UBS-seq method, and dramatically less damage than conventional bisulfite sequencing. In head-to-head library comparisons, UMBS-seq outperformed UBS-seq across nearly every metric — insert size, library yield, conversion efficiency, GC coverage uniformity, and methylation accuracy. UBS-seq still wins on reaction speed.
Outperforms EM-seq, the leading “gentle” enzymatic alternative
Benchmarked directly against NEB’s NEBNext EM-seq and Zymo’s EZ DNA Methylation-Gold kit using λ-DNA inputs ranging from as little as 10 pg to 5 ng, UMBS-seq delivered:
- Higher library yields at every input level tested, including at ultra-low 10-picogram input.
- Lower duplication rates (higher library complexity) than conventional bisulfite sequencing, and comparable to or better than EM-seq.
- Longer DNA insert sizes, comparable to EM-seq and far longer than conventional.
- Consistently low background of unconverted cytosines (~0.1%) across all input levels, with far greater consistency than EM-seq — which showed background exceeding 1% at the lowest inputs and a striking 7.6% of unmethylated CpG sites misclassified as unreliable, compared with just 0.34% for UMBS-seq.
The researchers traced EM-seq’s elevated background at low input to a subpopulation of reads with widespread failed C-to-U conversion, likely reflecting incomplete DNA denaturation and limited enzyme–substrate interaction at low DNA concentrations. That is an inherent weakness of enzymatic approaches, and one that UMBS-seq’s high-concentration bisulfite chemistry avoids.
Real-world performance on human cell-free DNA
Testing on pooled human plasma cfDNA across the same 10 pg – 5 ng input range showed that UMBS-seq:
- Preserved the classic triple-peak cfDNA fragment size profile.
- Produced significantly higher library yields and lower duplication rates than EM-seq at all tested inputs.
- Achieved comparable insert size distribution to EM-seq.
- Delivered better genomic coverage of GC-rich regulatory elements such as gene promoters and CpG islands than conventional bisulfite sequencing, and on par with EM-seq.
- Produced more accurate methylation-level estimates, since both enzymatic and conventional conversion showed inflated CpG methylation readings caused by incomplete conversion.
A proof-of-concept for clinical biomarker capture
The team combined UMBS-seq with a hybridization-based targeted methylation capture panel (µCaler EMS Panel v1.0, covering ~2,500 CpG sites linked to nine major cancers) using just 5 ng of cfDNA. UMBS-seq achieved significantly greater coverage of targeted CpG sites than EM-seq, demonstrating that its improved DNA integrity and conversion accuracy translate directly into better performance for targeted clinical methylation panels — a workflow highly relevant to liquid biopsy, including early cancer detection and MRD monitoring.
UMBS-seq vs. EM-seq vs. Conventional Bisulfite Sequencing
| Feature | CBS-seq (conventional)Zymo EZ DNA Methylation-Gold | EM-seq (enzymatic)NEBNext Enzymatic Methyl-seq | UMBS-seq (ultra-mild) |
|---|---|---|---|
| Workflow time | ~3 hours to overnight | ~8 hours to a full workday (multi-step) | 2–3 hours |
| DNA damage | Severe | Minimal | Minimal |
| Library yield at low input | Low | Moderate | High |
| Library complexity (duplication rate) | High duplication | Moderate | Low duplication |
| Background at low input | Moderate (<0.5%) | High (>1%, up to 7.6% unreliable CpGs) | Very low and consistent (~0.1%, 0.34% unreliable CpGs) |
| Methylation-level accuracy | Overestimates | Overestimates at low input | Accurate |
| Workflow complexity and cost | Simple, low-cost | Complex, expensive, enzyme-dependent | Simple |
Why This Matters Beyond the Lab
Liquid biopsy-based cancer detection, prenatal diagnostics, FFPE tissue archives, and single-cell epigenomics all share the same fundamental constraint: the DNA available is scarce, fragmented, or both. A conversion method that damages DNA further — or that relies on an enzyme whose efficiency drops off precisely when substrate is limiting — works against exactly the samples where accurate methylation detection matters most clinically. By demonstrating that mild bisulfite chemistry can match enzymatic methods on DNA preservation while retaining the speed, robustness, and low cost of bisulfite-based workflows, this paper offers a practical path toward more reliable methylation-based diagnostics from the hardest clinical low-input samples.
Read the Full Study
This summary covers the highlights, but the original paper includes the complete experimental methodology, additional supplementary data (GC-bias analysis, CpG coverage depth comparisons, reproducibility across replicates, and detailed protocol differences from UBS-seq), and full statistical reporting.
Original research
Dai, Q., Baldwin, T., Lyu, R., Daniels, B. et al. “Ultra-mild bisulfite outperforms existing methods for 5-methylcytosine detection with low input DNA.” Nature Communications 16, 9939 (2025).
From Academic Discovery to the Bench: SuperMethyl™ Max
The ultra-mild bisulfite (UMBS) chemistry described in this paper has been developed into a commercially available research-use-only (RUO) kit: the SuperMethyl™ Max Bisulfite Conversion Kit from Ellis Bio, which holds the exclusive license to the UMBS technology from the University of Chicago.
SuperMethyl™ Max brings this ultra-mild, low-input-optimized chemistry to any lab running methylation workflows, offering:
- A streamlined 2–3 hour total protocol, with up to 5× less hands-on time than enzyme-based methods like EM-seq
- 99.8% C-to-T conversion efficiency, supporting high-confidence methylation calling
- Enzyme-like DNA preservation, with library yields comparable to enzymatic methods and up to 3× higher than standard bisulfite kits
- Validated performance across inputs from 100 pg to 2 µg of cfDNA, gDNA, or FFPE-derived DNA
- Up to 6× fewer false positives than conventional bisulfite approaches
- Uniform GC coverage across promoters and other GC-rich regions
- Full compatibility with major NGS library prep kits and sequencing platforms
Try it in your workflow
Enzyme-like DNA preservation, without the enzymes
If your work involves DNA methylation biomarker discovery, FFPE methylation profiling, liquid biopsy panels, or any application where your DNA input is precious, fragmented, or limited — SuperMethyl™ Max was built specifically for that use case.
Learn more about SuperMethyl™ MaxFrequently Asked Questions
What is UMBS-seq?
UMBS-seq (ultra-mild bisulfite sequencing) is a DNA methylation sequencing method that combines an optimized bisulfite recipe with a low-temperature incubation reaction (55 °C for 90 minutes) and a DNA protection buffer to achieve efficient cytosine-to-uracil conversion while minimizing DNA degradation.
How is UMBS-seq different from UBS-seq?
UBS-seq (ultrafast bisulfite sequencing), the same team’s earlier method, uses very high temperature (98 °C) for a very short time (under 10 minutes) to speed up conversion. UMBS-seq instead uses a milder, lower-temperature, slightly longer reaction along with a new bisulfite recipe and a DNA protection buffer, resulting in substantially less DNA damage, higher library yield and complexity, and more accurate methylation measurements — at the cost of a somewhat longer reaction time, though still faster than most CBS-seq methods available.
Is UMBS-seq better than EM-seq (enzymatic methyl-sequencing)?
In this study, UMBS-seq outperformed NEB’s NEBNext EM-seq on multiple metrics at low DNA inputs, including higher library yield and complexity, lower and more consistent background noise, and more accurate methylation-level estimation — all while avoiding EM-seq’s enzyme-related variability, workflow complexity, and higher reagent costs.
Can UMBS-seq be used on cell-free DNA (cfDNA) for clinical biomarker research?
Yes. UMBS-seq performed well on cfDNA across inputs from 5 ng down to 10 pg, and when combined with a targeted methylation capture panel for cancer-related CpG sites, it achieved significantly greater target coverage than both EM-seq and conventional bisulfite sequencing.
Is the UMBS-seq method available as a commercial kit?
Yes. The underlying ultra-mild bisulfite chemistry has been developed into the commercially available SuperMethyl™ Max Bisulfite Conversion Kit from Ellis Bio, which holds the exclusive global license to the technology from the University of Chicago.
Is SuperMethyl™ Max better than EM-seq v2?
In a recent Tech Spotlight, Roche independently demonstrated that SuperMethyl™ Max performed better than the NEBNext® Enzymatic Methyl-seq v2 Kit on metrics including C-to-T conversion efficiency, library yield, and methylation accuracy. The Roche study tested both 1 ng cfDNA and 10 ng gDNA inputs. In particular, SuperMethyl™ Max showed a 6.7× lower false-positive rate than the NEBNext® Enzymatic Methyl-seq v2 Kit.
